Advances in blood–brain barrier modeling in microphysiological systems highlight critical differences in opioid transport due to cortisol exposure

[1]  N. Voelcker,et al.  Advances in Microfluidic Blood-Brain Barrier (BBB) Models. , 2019, Trends in biotechnology.

[2]  Sean P. Palecek,et al.  An isogenic neurovascular unit model comprised of human induced pluripotent stem cell-derived brain microvascular endothelial cells, pericytes, astrocytes, and neurons , 2019, Fluids and Barriers of the CNS.

[3]  Sean P. Palecek,et al.  Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies , 2019, Nature Communications.

[4]  Kylie M. Balotin,et al.  A Simplified, Fully Defined Differentiation Scheme for Producing Blood-Brain Barrier Endothelial Cells from Human iPSCs , 2019, Stem cell reports.

[5]  S. Hwang,et al.  Effects of surgery start time on postoperative cortisol, inflammatory cytokines, and postoperative hospital day in hip surgery , 2019, Medicine.

[6]  A. Sehgal,et al.  Endocytosis at the Drosophila blood–brain barrier as a function for sleep , 2018, eLife.

[7]  Sean P Sheehy,et al.  A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells , 2018, Nature Biotechnology.

[8]  A. Sehgal,et al.  A Circadian Clock in the Blood-Brain Barrier Regulates Xenobiotic Efflux , 2018, Cell.

[9]  U. Pirunsan,et al.  Immediate Effects of Core Stabilization Exercise on &bgr;‐Endorphin and Cortisol Levels Among Patients With Chronic Nonspecific Low Back Pain: A Randomized Crossover Design , 2018, Journal of manipulative and physiological therapeutics.

[10]  Koji Ando,et al.  A molecular atlas of cell types and zonation in the brain vasculature , 2018, Nature.

[11]  M. Tome,et al.  The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse , 2017, Fluids and Barriers of the CNS.

[12]  M. Morris,et al.  SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers , 2017, The AAPS Journal.

[13]  E. Lippmann,et al.  Accelerated differentiation of human induced pluripotent stem cells to blood–brain barrier endothelial cells , 2017, Fluids and Barriers of the CNS.

[14]  Orlando S. Hoilett,et al.  Metabolic consequences of inflammatory disruption of the blood-brain barrier in an organ-on-chip model of the human neurovascular unit , 2016, Journal of Neuroinflammation.

[15]  Qing Yang,et al.  Recreating blood-brain barrier physiology and structure on chip: A novel neurovascular microfluidic bioreactor. , 2015, Biomicrofluidics.

[16]  H. Oster,et al.  Circadian Clocks and the Interaction between Stress Axis and Adipose Function , 2015, International journal of endocrinology.

[17]  Alf Lamprecht,et al.  Coadministration of P-Glycoprotein Modulators on Loperamide Pharmacokinetics and Brain Distribution , 2014, Drug Metabolism and Disposition.

[18]  Sean P. Palecek,et al.  A retinoic acid-enhanced, multicellular human blood-brain barrier model derived from stem cell sources , 2014, Scientific Reports.

[19]  Alon Friedman,et al.  Overview and introduction: The blood–brain barrier in health and disease , 2012, Epilepsia.

[20]  Sean P. Palecek,et al.  Human Blood-Brain Barrier Endothelial Cells Derived from Pluripotent Stem Cells , 2012, Nature Biotechnology.

[21]  E. Bruera,et al.  Association between serum cortisol and testosterone levels, opioid therapy, and symptom distress in patients with advanced cancer. , 2011, Journal of pain and symptom management.

[22]  Nicolas Tournier,et al.  Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). , 2010, The international journal of neuropsychopharmacology.

[23]  David S. Miller,et al.  Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. , 2010, Trends in pharmacological sciences.

[24]  Thomas J. Raub,et al.  Rhodamine inhibitors of P-glycoprotein: an amide/thioamide "switch" for ATPase activity. , 2009, Journal of medicinal chemistry.

[25]  C. Pariante,et al.  A revised role for P-glycoprotein in the brain distribution of dexamethasone, cortisol, and corticosterone in wild-type and ABCB1A/B-deficient mice. , 2008, Endocrinology.

[26]  T. Terasaki,et al.  Involvement of the Pyrilamine Transporter, a Putative Organic Cation Transporter, in Blood-Brain Barrier Transport of Oxycodone , 2008, Drug Metabolism and Disposition.

[27]  Eric V Shusta,et al.  In vitro models of the blood–brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  T. Terasaki,et al.  A functional in vitro model of rat blood–brain barrier for molecular analysis of efflux transporters , 2007, Brain Research.

[29]  U. Simonsson,et al.  In Vivo Blood-Brain Barrier Transport of Oxycodone in the Rat: Indications for Active Influx and Implications for Pharmacokinetics/Pharmacodynamics , 2006, Drug Metabolism and Disposition.

[30]  Helga E de Vries,et al.  Puromycin‐purified rat brain microvascular endothelial cell cultures exhibit improved barrier properties in response to glucocorticoid induction , 2006, Journal of neurochemistry.

[31]  H. Galla,et al.  Murine brain capillary endothelial cells exhibit improved barrier properties under the influence of hydrocortisone , 2005, Brain Research.

[32]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[33]  U. Simonsson,et al.  Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. , 2005, Journal of pharmaceutical sciences.

[34]  G. Fricker,et al.  Modulation of Drug Transporters at the Blood-Brain Barrier , 2004, Pharmacology.

[35]  P. Jenner,et al.  The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates , 2004, Movement disorders : official journal of the Movement Disorder Society.

[36]  J. Temsamani,et al.  Evidence for an active transport of morphine‐6‐β‐d‐glucuronide but not P‐glycoprotein‐mediated at the blood–brain barrier , 2003, Journal of neurochemistry.

[37]  R. Kim,et al.  Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein , 2002, Anesthesiology.

[38]  R. Egleton,et al.  Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier , 2001, Trends in Neurosciences.

[39]  R Hori,et al.  Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. , 1992, The Journal of biological chemistry.

[40]  A. Butt,et al.  Calcium-dependent regulation of potassium permeability in the glial perineurium (blood-brain barrier) of the crayfish , 1990, Neuroscience.

[41]  Thomas S. Reese,et al.  FINE STRUCTURAL LOCALIZATION OF A BLOOD-BRAIN BARRIER TO EXOGENOUS PEROXIDASE , 1967, The Journal of cell biology.

[42]  Eve M. Taylor,et al.  The Impact of Efflux Transporters in the Brain on the Development of Drugs for CNS Disorders , 2002, Clinical pharmacokinetics.

[43]  M. Brightman,et al.  Nonpermeable and permeable vessels of the brain. , 1992, NIDA research monograph.